Trials / Completed
CompletedNCT00191360
Extension Study on Safety of Long-Term Growth Hormone Replacement in Adult Patients With Growth Hormone Deficiency
Extended Clinical Study of LY137998 [Somatropin (Recombinant DNA Origin)] in Adults With Growth Hormone Deficiency
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 68 (planned)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate long-term safety of growth hormone replacement in adult patients with growth hormone deficiency
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Somatropin |
Timeline
- Start date
- 2003-01-01
- Completion
- 2006-05-01
- First posted
- 2005-09-19
- Last updated
- 2007-11-06
Locations
14 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00191360. Inclusion in this directory is not an endorsement.